Athenex (ATNXQ) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 27, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	ATNX
Entity Registrant Name	ATHENEX, INC.
Entity Central Index Key	1,300,699
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		57,995,264

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 19,262	$ 33,125
Short-term investments	49,781	8,628
Accounts receivable, net of chargebacks, allowance for doubtful accounts, and other deductions of $2,832 and $155, respectively	6,459	2,777
Inventories	11,635	4,240
Prepaid expenses and other current assets	5,876	3,153
Total current assets	93,013	51,923
Property and equipment, net	8,824	5,810
Goodwill	37,691	37,552
Intangible assets, net	8,905	8,464
Other long-term assets	325	2,141
Total assets	148,758	105,890
Current liabilities:
Accounts payable	6,622	7,174
Accrued expenses	21,594	18,956
Current portion of long-term debt - related parties	779	1,123
Current portion of long-term debt	842	766
Total current liabilities	29,837	28,019
Long-term liabilities:
Deferred compensation	2,199	2,174
Deferred rent	1,544	904
Deferred income tax liability	99	206
Capital lease obligation	179
Long-term debt - related parties		496
Convertible bonds		14,498
Convertible bonds - related parties		16,129
Derivative liability		8,795
Total liabilities	33,858	71,221
Commitments and contingencies (Note 14)
Stockholders' equity:
Common stock, par value $0.001 per share, 250,000,000 shares authorized at September 30, 2017 and December 31, 2016; 59,668,184 and 42,342,706 shares issued at September 30, 2017 and December 31, 2016, respectively; 57,995,264 and 40,685,786 shares outstanding at September 30, 2017 and December 31, 2016, respectively	60	42
Additional paid-in capital	419,854	237,581
Accumulated other comprehensive loss	(412)	(1,304)
Accumulated deficit	(297,993)	(195,106)
Less: treasury stock, at cost; 1,672,920 and 1,656,920 shares at September 30, 2017 and December 31, 2016, respectively	(7,406)	(7,406)
Total Athenex, Inc. stockholders' equity	114,103	33,807
Non-controlling interests	797	862
Total stockholders' equity	114,900	34,669
Total liabilities and stockholders' equity	$ 148,758	$ 105,890

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, chargebacks, allowance for doubtful accounts, and other deductions (in dollars)	$ 2,832	$ 155
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	59,668,184	42,342,706
Common Stock, shares outstanding	57,995,264	40,685,786
Treasury stock, shares	1,672,920	1,656,920

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Product sales, net	$ 13,662	$ 5,235	$ 21,978	$ 14,543
License fees and consulting revenue	60	76	756	242
Grant revenue	272	305	436	653
Total revenue	13,994	5,616	23,170	15,438
Costs and operating expenses:
Cost of product sales	8,082	5,416	15,058	14,392
Research and development expenses	11,944	18,052	55,949	33,443
Selling, general, and administrative expenses	10,364	6,790	33,795	15,694
Total costs and operating expenses	30,390	30,258	104,802	63,529
Operating loss	(16,396)	(24,642)	(81,632)	(48,091)
Interest expense	353	5	6,010	8
Loss on derivative liability	6,548		15,411
Loss before income tax expense (benefit)	(23,297)	(24,647)	(103,053)	(48,099)
Income tax expense (benefit)	11	9	(52)	(294)
Net loss	(23,308)	(24,656)	(103,001)	(47,805)
Less: net loss attributable to non-controlling interests	(34)	(34)	(114)	(144)
Net loss attributable to Athenex, Inc.	(23,274)	(24,622)	(102,887)	(47,661)
Unrealized gain (loss) on investment, net of income taxes	4	(1)	(30)	62
Foreign currency translation adjustment, net of income taxes	242	(50)	922	(477)
Comprehensive loss	$ (23,028)	$ (24,673)	$ (101,995)	$ (48,076)
Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted	$ (0.41)	$ (0.61)	$ (2.18)	$ (1.20)
Weighted-average shares used in computing net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted	57,134,889	40,261,551	47,238,452	39,464,530

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury Stock	Total Athenex, Inc. Stockholders' Equity	Non-Controlling Interests
Beginning balance at Dec. 31, 2015	$ 98,044	$ 40	$ 206,679	$ (107,391)	$ (223)	$ (1,545)	$ 97,560	$ 484
Beginning balance, shares at Dec. 31, 2015		40,330,124				(422,328)
Issuance/sale of common stock	8,500	$ 1	8,499				8,500
Issuance/sale of common stock, shares		1,133,332
Issuance of common stock in connection with satisfaction of contingent consideration	2,843	$ 1	2,842				2,843
Issuance of common stock in connection with satisfaction of contingent consideration, shares		315,810
Stock-based compensation cost	6,196		6,196				6,196
Restricted stock expense	3,973		3,973				3,973
Repurchase of common stock, at cost	(2,311)					$ (2,311)	(2,311)
Repurchase of common stock, shares						(265,200)
Stock options exercised	14		14				14
Stock options exercised, shares		5,440
Non-controlling interests	569							569
Net loss	(47,805)			(47,661)			(47,661)	(144)
Other comprehensive income (loss), net of tax	(415)				(415)		(415)
Ending balance at Sep. 30, 2016	69,608	$ 42	228,203	(155,052)	(638)	$ (3,856)	68,699	909
Ending balance, shares at Sep. 30, 2016		41,784,706				(687,528)
Beginning balance at Dec. 31, 2016	34,669	$ 42	237,581	(195,106)	(1,304)	$ (7,406)	33,807	862
Beginning balance, shares at Dec. 31, 2016		42,342,706				(1,656,920)
Issuance/sale of common stock	64,194	$ 7	64,187				64,194
Issuance/sale of common stock, shares		6,900,000
Conversion of bonds	98,929	$ 9	98,920				98,929
Conversion of bonds, shares		8,522,728
Stock-based compensation cost	10,090		10,090				10,090
Stock-based compensation cost, shares		400,000
Research and development licensing fee satisfied with stock	6,250	$ 1	6,249				6,250
Research and development licensing fee satisfied with stock, shares		568,182
Vesting of restricted stock	1,620	$ 1	1,619				1,620
Vesting of restricted stock, shares		421,982
Stock options and warrants exercised	$ 1,208		1,208				1,208
Stock options and warrants exercised, shares		512,586
Repurchase of common stock, shares						(16,000)
Stock options exercised, shares	178,520
Non-controlling interests	$ 49							49
Net loss	(103,001)			(102,887)			(102,887)	(114)
Other comprehensive income (loss), net of tax	892				892		892
Ending balance at Sep. 30, 2017	$ 114,900	$ 60	$ 419,854	$ (297,993)	$ (412)	$ (7,406)	$ 114,103	$ 797
Ending balance, shares at Sep. 30, 2017		59,668,184				(1,672,920)

CONSOLIDATED STATEMENTS OF STO6

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Statement Of Stockholders Equity [Abstract]
Stock issuance costs and discounts	$ 11,706

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (103,001)	$ (47,805)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,585	1,330
Stock-based compensation expense	11,710	10,169
Change in fair value of contingent consideration		53
Change in fair value of derivative liability	15,411
Amortization of debt discount	3,349
Deferred rent expense	640
Loss on disposal of assets and impairment charges	80	937
Research and development license fees settled with convertible bond and stock	13,250
Interest incurred on converted bonds	2,759
Deferred income taxes	(108)	(397)
Changes in operating assets and liabilities:
Receivables, net	(3,682)	301
Prepaid expenses and other assets	(2,722)	(1,432)
Inventories, net	(7,395)	(960)
Accounts payable and accrued expenses	3,480	2,638
Net cash used in operating activities	(63,644)	(35,166)
Cash flows from investing activities:
Purchase of property and equipment	(4,384)	(1,120)
Receipt of deposit	80	1,000
Payments for licenses	(1,550)	(2,700)
Purchases of short-term investments	(55,282)	(9,750)
Sale of short-term investments	14,114	10,326
Net cash used in investing activities	(47,022)	(2,244)
Cash flows from financing activities:
Proceeds from sale of stock	75,900	8,500
Proceeds from issuance of convertible bonds	30,000	35,000
Costs incurred related to the sale of stock	(10,168)
Proceeds from exercise of stock options	1,208	14
Investment from non-controlling interest	49	569
Payment of contingent consideration		(3,185)
Repayment of capital lease obligations and long-term debt	(896)	(964)
Purchase of treasury stock		(2,311)
Net cash provided by financing activities	96,093	37,623
Net (decrease) increase in cash and cash equivalents	(14,573)	213
Cash and cash equivalents, beginning of period	33,125	43,495
Effect of exchange rate changes on cash and cash equivalents	710	(177)
Cash and cash equivalents, end of period	19,262	43,531
Non-cash investing and financing activities:
Accrued purchases of property and equipment	150	57
Cost of equity raise in accounts payable and accrued expenses		327
Convertible bond issued in lieu of licensing cash payment	7,000
Common stock issued in lieu of licensing cash payment	6,250
Common stock issued upon the conversion of bonds	98,929
Property and equipment financed under capital lease	$ 242
QuaDPharma
Non-cash investing and financing activities:
Stock issued in connection with acquisition		343
Polymed
Non-cash investing and financing activities:
Stock issued in connection with acquisition		$ 2,500

Company and Nature of Business

Company and Nature of Business	9 Months Ended
	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Company and Nature of Business	1. Company and Nature of Business Organization and Description of Business Athenex, Inc. (the “Company” or “Athenex”), originally known as Kinex Pharmaceuticals LLC, formed in November 2003, commenced operations on February 5, 2004, and operated as a limited liability company until it was incorporated in the State of Delaware under the name Kinex Pharmaceuticals, Inc. on December 31, 2012. The Company changed its name to Athenex, Inc. on August 26, 2015. Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The Company has generated its clinical product candidates through its Orascovery and Src Kinase Inhibition research platforms, which are based on its understanding of human absorption biology and novel approaches to inhibiting kinase activity, respectively. The Company has assembled a leadership team and has established operations in the U.S. and China across the pharmaceutical value chain to execute its mission to become a global leader in bringing innovative cancer treatments to the market and improving health outcomes. The Company’s primary activities since commencement have been conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, and conducting clinical trials. Significant Risks and Uncertainties The Company has incurred operating losses since its inception and, as a result, as of December 31, 2016 and September 30, 2017 had an accumulated deficit of $195.1 million and $298.0 million, respectively. Operations have been funded primarily through the sale of common stock and convertible bonds and, to a lesser extent, through revenue generated from our Global Supply Chain Platform and Commercial Platform. The Company will require significant additional funds in order to conduct clinical trials and to fund its operations. There can be no assurances, however, that additional funding will be available on favorable terms, or at all. If adequate funds are not available, the Company may be required to delay, modify, or terminate its research and development programs or reduce its planned commercialization efforts. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund operations. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans. Accordingly, there is substantial doubt regarding the Company’s ability to continue as a going concern. These consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of the business. The Company’s recurring losses from operations and negative cash flows from operations have raised substantial doubt regarding its ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Athenex is subject to a number of risks similar to other biopharmaceutical companies, including, but not limited to, the lack of available capital, possible failure of preclinical testing or clinical trials, inability to obtain marketing approval of product candidates, competitors developing new technological innovations, market acceptance of the Company’s products, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate sufficient product revenue to achieve profitability. Initial Public Offering On June 13, 2017, the Company’s Registration Statement on Form S-1 (File No. 333-217928) relating to the initial public offering (“IPO”) of its common stock was declared effective by the Securities and Exchange Commission (“SEC”). Pursuant to such Registration Statement, the Company sold an aggregate of 6,900,000 shares of its common stock at a price of $11.00 per share for cash proceeds of $64.2 million, net of underwriting discounts and commissions of $6.1 million and offering costs of $5.6 million. On June 14, 2017, the day of the IPO, convertible bonds with an aggregate principal value of $68.0 million, and a carrying value of $55.8 million, were converted into 7,727,273 shares of common stock. The IPO closed on June 19, 2017. On September 29, 2017, the remaining convertible bond with a principal value of $7.0 million was converted into 795,455 shares of common stock, at a 20% discount from the IPO price of $11 per share.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments ) considered necessary for a fair presentation of the results of the Company for the periods presented. These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. Intercompany transactions and balances have been fully eliminated in consolidation. Results of the operations for the three and nine months ended September 30, 2017 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes for the years ended December 31, 2015 and 2016 included in the prospectus dated June 15, 2017, filed with the SEC pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended. Use of Estimates These condensed consolidated financial statements have been prepared in conformity with GAAP. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in contract research accruals, allowance for doubtful accounts, chargebacks, inventory reserves, income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards. Actual results could differ from those estimates. Revenue Recognition Product Sales, Chargebacks, Returns, and Discounts The Company recognizes product revenue when there is persuasive evidence of an arrangement, the price is fixed or determinable, collectability is reasonably assured, and upon shipment to or delivery and acceptance by customers. Service revenue is recognized in the period such services have been rendered. The Company’s specialty products sold through its Commercial Platform are distributed through independent pharmaceutical wholesalers. The wholesalers then generally sell to an end-user, normally a hospital, alternative healthcare facility, or an independent pharmacy, at a lower price previously established by the end-user and the Company. Sales are initially recorded at the list price sold to the wholesaler. Because these prices will be reduced for the end-user, the Company records a contra asset in accounts receivable and a reduction to revenue at the time of the sale, using the difference between the list price and the estimated end-user contract price. Upon the sale by the wholesaler to the end-user, the wholesaler will chargeback the difference between the original list price and price at which the product was sold to the end-user and such chargeback is offset against the initial estimated contra asset. As of September 30, 2017, the Company’s chargeback provision totaled $2.6 million. The Company offers cash discounts, which approximate 2% of the gross sales price as an incentive for prompt customer payment, and, consistent with industry practice, the Company’s return policy permits customers to return products within a window of time before and after the expiration of product dating, most often 2% of gross purchases. The Company expects that its wholesale customers will make timely payments and take advantage of the cash discounts, and expects customers to use their right of return. Therefore, at the time of sale, product revenue and accounts receivable are reduced by the full amount of the discount offered and the return expected. The Company considers payment performance and historical return rates and adjusts the accrual to reflect actual experience. As of September 30, 2017, the Company’s accrual for cash discounts and return accrual were not material to the financial statements. Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and investments. The Company deposits its cash equivalents in interest-bearing money market accounts and certificates of deposit. Although the Company deposits the cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility in China, Taihao, and therefore is subject to foreign currency fluctuation. Also, due to government restrictions on transferring funds out of China, the total restricted net assets of the Company’s consolidated subsidiaries was $12.7 million and $15.7 million as of September 30, 2017 and December 31, 2016, respectively. Recent Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) No. 2014-09, “ Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued ASU No. 2016-02, “ Leases (Topic 842) In June 2016, the FASB issued ASU No. 2016-13, “ Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In October 2016, the FASB issued ASU 2016-16, “ Income Taxes (Topic 740): Intra-entity Transfers of Assets Other Than Inventory In November 2016, the FASB issued ASU 2016-18, “ Statement of Cash Flows (Topic 230): Restricted Cash In May 2017, the FASB issued ASU 2017-09, “ Stock Compensation - Scope of Modification Accounting Recently Adopted Accounting Pronouncements In July 2015, the FASB issued ASU No. 2015-11, “ Inventory (Topic 330): Simplifying the Measurement of Inventory. In March 2016, the FASB issued ASU No. 2016-09, “ Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In January 2017, the FASB issued ASU 2017-04, “ Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment

Inventories

Inventories	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Inventories	3. Inventories Inventories consist of the following (in thousands): September 30, 2017 December 31, 2016 Raw materials and purchased parts $ 934 $ 977 Work in progress 2,298 2,727 Finished goods 8,403 536 Total inventories $ 11,635 $ 4,240

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Sep. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets, net	4. Intangible Assets, net The Company’s identifiable intangible assets, net, consist of the following (in thousands): December 31, 2016 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 3,100 $ 315 $ - $ 2,785 QuaDPharma customer list 204 58 146 - Polymed customer list 1,593 414 - 1,179 Polymed technology 3,712 437 - 3,275 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,884 - 248 1,636 Effect of currency translation adjustment (411 ) - - (411 ) Total intangible assets, net $ 10,082 $ 1,224 $ 394 $ 8,464 September 30, 2017 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 4,650 $ 952 $ - $ 3,698 Polymed customer list 1,593 611 - 982 Polymed technology 3,712 672 - 3,040 Product rights 530 100 - 430 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,106 - 80 1,026 Effect of currency translation adjustment (271 ) - - (271 ) Total intangible assets, net $ 11,320 $ 2,335 $ 80 $ 8,905 As of December 31, 2016, licenses at cost include an Orascovery license of $0.4 million and a license purchased from Gland Pharma Ltd (“Gland”) of $2.7 million. The Orascovery license with Hanmi Pharmaceuticals Co. Ltd. (“Hanmi”) was purchased directly from Hanmi and is being amortized on a straight-line basis over a period of 12.75 years, the remaining life of the license agreement at the time of purchase. The license purchased from Gland is being amortized on a straight-line basis over a period of 5 years, the remaining life of the license agreement at the time of purchase. During the nine months ended September 30, 2017, the Company purchased additional licenses from Gland for $1.6 million which are being amortized over a period of 5 years. The remaining intangible assets were acquired in connection with the acquisitions of Athenex Pharma Solutions (formerly referred to as QuaDPharma), Polymed, and CDE. Intangible assets are amortized using an economic consumption model over their useful lives. The Athenex Pharma Solutions customer list was being amortized on a straight-line basis over 7 years. The Polymed customer list and technology are amortized on a straight-line basis over 6 and 12 years, respectively. The CDE in-process research and development, or IPR&D, will not be amortized until the related projects are completed. IPR&D will be tested annually for impairment, unless conditions exist causing an earlier impairment test (i.e. abandonment of project). During the nine months ended September 30, 2017, the Company abandoned a project within IPR&D and therefore, the related balance of $0.1 million was written-off as impaired and is included within research and development expenses in the condensed consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2017. The weighted-average useful life for all intangible assets was 7.91 years as of September 30, 2017. The Company recorded $0.4 million and $0.2 million of amortization expense for the three months ended September 30, 2017 and 2016, respectively, and $1.2 million and $0.5 million of amortization expense for the nine months ended September 30, 2017 and 2016, respectively.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements Financial instruments consist of cash and cash equivalents, short-term investments, an equity investment, accounts receivable, accounts payable, accrued liabilities, and debt. Short-term investments, the equity investment, and the embedded derivative liability are stated at fair value. Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and debt, are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date of such amounts. ASC 820, Fair Value Measurements, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under the ASC 820 are described as follows: Level 1 —Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2 —Inputs to the valuation methodology include: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets or liabilities in inactive markets; • Inputs other than quoted prices that are observable for the asset or liability; • Inputs that are derived principally from or corroborated by observable market data by correlation or other means; and • If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3 —Inputs to the valuation methodology are unobservable, supported by little or no market activity, and are significant to the fair value measurement. Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs. There were no transfers between Levels 1, 2 or 3 for any of the periods presented. The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at December 31, 2016 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 6,522 $ 6,522 $ - $ - Short-term investments - certificates of deposit 8,628 8,628 - - Investment 340 340 - - Total assets $ 15,490 $ 15,490 $ - $ - Liabilities: Derivative liability $ 8,795 $ - $ - $ 8,795 Total liabilities $ 8,795 $ - $ - $ 8,795 Fair Value Measurements at September 30, 2017 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 7,706 $ 7,706 $ - $ - Short-term investments - commercial paper 22,198 - 22,198 - Short-term investments - corporate notes 10,084 - 10,084 - Short-term investments - U.S. government bonds 19,498 - 19,498 - Investment 325 325 - - Total assets $ 59,811 $ 8,031 $ 51,780 $ - The Company classifies its certificates of deposit and money market funds within Level 1 because it uses quoted market prices to determine their fair value. The Company classifies its commercial paper, corporate notes, and U.S. government bonds within Level 2 because it uses quoted prices for similar assets or liabilities in active markets and each has a specified term and all level 2 inputs are observable for substantially the full term of each instrument. The Company owns 68,000 shares of PharmaEssentia, a company publicly traded on the Taiwan OTC Exchange (“TWO”). As of September 30, 2017 and December 31, 2016, the Company’s investment in PharmaEssentia is valued at the closing price reported on the TWO. This investment is classified as a level 1 investment. The Company bifurcated the embedded derivative feature from its convertible bonds and recorded it as a long-term liability. The derivative liability was measured at fair value as of the issuance date and remeasured at fair value at the end of the reporting period. The liability is measured at fair value using level 3 inputs. The derivative liability is discussed further in Note 7— Debt . The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments (in thousands): Derivative Liability Balance as of December 31, 2016 $ 8,795 Issuance of convertible bonds with embedded derivative 13,172 Change in fair value 15,411 Conversion of derivative liability to common stock (37,378 ) Balance as of September 30, 2017 $ -

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes The Company did not record a provision for federal income taxes for the nine months ended September 30, 2017 because it expects to generate a loss for the year ending December 31, 2017 and the Company’s net deferred tax assets continue to be offset by a full valuation allowance. Tax benefit to date relates to foreign tax benefit on losses in the Peoples Republic of China (“PRC”) offset by state franchise taxes and amortization of long-lived intangible assets in the U.S. and PRC.

Debt

Debt	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Debt	7. Debt As of September 30, 2017 and December 31, 2016, the balances of this debt are as follows (in thousands): September 30, 2017 December 31, 2016 Current portion of promissory notes to related parties $ 779 $ 1,123 Current portion of mortgage 798 766 Current portion of capital lease obligation 44 - Long-term portion of promissory notes to related parties - 496 Long-term portion of capital lease obligation 179 - Convertible bonds - 14,498 Convertible bonds - related parties - 16,129 Derivative liability - 8,795 Total $ 1,800 $ 41,807 The promissory notes have a 36-month term beginning on July 1, 2015 and ending on June 1, 2018 with a 6% stated interest rate. The mortgage payments extend through July 30, 2018. Future minimum principal payments on these promissory notes and mortgage consist of $1.1 million and $0.5 million due in the remaining three months in 2017 and 2018, respectively. In 2016 and 2017, the Company issued convertible bonds with an aggregate principal value of $75.0 million and a maturity date of October 1, 2018. Of the convertible bonds issued, an aggregate principal of $24.0 million were issued to related parties. On June 14, 2017, the IPO date, $68.0 million of these bonds, which had a carrying value of $55.8 million, were converted into 7,727,273 shares of common stock. In March 2017, the Company signed an amendment to its license agreement with Hanmi, under which the Company received the rights to develop and sell drugs under the Orascovery program in additional territories, including Japan. This license amendment required an upfront fee of $7.0 million payable to Hanmi upon the execution of the agreement. In lieu of the payment, the Company issued a convertible bond to Hanmi with a par value of $7.0 million. This bond carried an interest rate of 10% per annum and a maturity date of October 1, 2018. This amendment included additional regulatory milestone payments and royalties based on sales. The occurrence of any milestone triggering events have not been deemed to be probable and no sales have yet occurred. On September 29, 2017, Hanmi converted its bond with a principal value of $7.0 million into 795,455 shares of common stock , at a 20% discount from the IPO price of $11 per share, which resulted in a loss on the embedded derivative feature from the convertible bond of $6.5 million in the three months ended September 30, 2017.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	8. Related Party Transactions During the three and nine months ended September 30, 2017 and 2016, the Company entered into transactions with individuals and companies that have financial interests in the Company. Related party transactions included the following: a. During 2014 and 2015, the Company issued promissory notes to two executives in the amount of $12.6 million to facilitate the executives’ purchase of the Company’s common stock. The notes were intended to be forgiven over a three-year period, as compensation to those executives. The Company accelerated the forgiveness of these promissory notes in 2016 and forgave the notes in full. Stock-based compensation expense related to these notes amounted to $0 and $1.0 million for the three months ended September 30, 2017 and 2016, respectively, and $0 and $3.1 million for the nine months ended September 30, 2017 and 2016, respectively. Further, certain family members of executives perform consulting services for the Company. Such services were not significant to the condensed consolidated financial statements. b. In 2015, CDE signed an agreement with Avalon BioMedical (Management) (“Avalon”) under which Avalon will receive certain administrative services and will occupy space at CDE’s research location. Avalon reimburses CDE for these administrative services as incurred and pays CDE a certain percentage of the total rent payment based on its staff headcount occupying the Hong Kong research and development facility (See Note 14— Commitments and Contingencies c. The Company receives consulting and licensing revenue from PharmaEssentia, a company in which Athenex has an investment classified as available-for-sale (see Note 5— Fair Value Measurements d. The Company previously purchased pharmaceutical ingredients from Chongqing Taisheng Biotechnology Co., Ltd. (“Taisheng”), a company which is owned by a member of Athenex’s management. The Company made no purchases from Taisheng the three months ended September 30, 2017 or 2016 nor in the nine months ended September 30, 2017, but did purchase $0.2 million for the nine months ended September 30, 2016. e. The Company receives clinical development services from ZenRx Limited and subsidiaries (“ZenRx”), a company for which one of our executive officers serves on the board of directors. In connection with such services, the Company made payments to ZenRx of $0.2 million and less than $0.1 million during the three months ended September 30, 2017 and 2016, respectively, and $0.5 million and less than $0.1 million during the nine months ended September 30, 2017 and 2016, respectively. As of each of September 30, 2017 and December 31, 2016, the Company owed ZenRx $0.1 million. f. The Company receives consulting services from RSJ Consulting LLC (“RSJ”), a limited liability company for which one of our executive officers serves as the principal. Services incurred from RSJ amounted to less than $0.1 million and less than $0.1 million for the three months ended September 30, 2017 and 2016, respectively, and $0.1 million and $0.2 million for the nine months ended September 30, 2017 and 2016, respectively. g. The Company issued and sold $24.0 million in convertible bonds in 2016 and 2017 to related parties. One of the holders of more than 5% of our outstanding common stock as of December 31, 2016, and an entity affiliated with one of our directors, each purchased $10.0 million in convertible bonds during 2016. Additionally, during the first quarter of 2017, the Company issued and sold $4.0 million in convertible bonds to two related parties. One of the holders of more than 5% of our outstanding common stock as of March 31, 2017 and a director of the Company each purchased $2.0 million in convertible bonds. On June 14, 2017, the IPO date, these bonds were converted into 2,727,273 shares of common stock.

Business and Economic Collabora

Business and Economic Collaborative Agreements	9 Months Ended
	Sep. 30, 2017
Text Block [Abstract]
Business and Economic Collaborative Agreements	9. Business and Economic Collaborative Agreements New York State On May 1, 2015, the Company executed an agreement for a medical technology research, development, innovation, and commercialization alliance with Fort Schuyler Management Corporation (“FSMC”), a not-for-profit corporation existing under the laws of the State of New York (the “State”). The Company has been granted $25 million by the State to build new corporate offices including a formulation lab with related equipment for the Company. The Company, through its partnership with FSMC, Empire State Development (“ESD”), and The State University of New York (“SUNY”) Polytechnic, plans to execute a major expansion and establish a 315,000 square foot, ISO Class 5 high potency oral and sterile injectable pharmaceutical manufacturing facility in Dunkirk, New York. On September 4, 2017, the Company entered into a Grant Disbursement Agreement whereby the State will grant up to $200 million, plus any additional funds available from the previous $25 million ESD Grant for the Company’s corporate offices, to fund the construction of the new pharmaceutical manufacturing facility. The Company is entitled to lease the facility and all equipment purchased with grant funds at a rate of $1.00 per year for an initial 10-year term, and for the same rate if the Company elects to extend the lease for an additional 10-year term. In exchange, the Company committed to spending $1.52 billion on operational expenses in the facility in its first 10-year term, and an additional $1.50 billion on operational expenses if the Company elects to extend the lease for a second 10-year term. The Company does not have significant construction period risks and the State will fund a majority of the construction costs and hold ownership of the manufacturing and office facilities. As of September 30, 2017, construction on these facilities had not yet been completed.

Stockholders Equity

Stockholders Equity	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Stockholders’ Equity	10. Stockholders’ Equity Common Stock As of September 30, 2017 and 2016, 250 million common shares, par value $0.001, were authorized by the Company’s Board of Directors. The common shares are entitled to one vote per share and to receive dividends as declared. On June 14, 2017, the Company completed an IPO of its common stock (refer to Note 1 – Company and Nature of Business for additional information). During the nine months ended September 30, 2017, the Company issued 6,900,000 shares of common stock at $11.00 per share in connection with the IPO, 8,522,728 shares of common stock from the conversion of the convertible bonds into common stock, 568,182 shares of common stock upon the IPO in connection with a licensing agreements, 512,586 shares from the exercise of warrants and options, and 821,982 shares from the vesting of restricted stock units and the grant of shares in connection with an executive’s employment agreement for cumulative increase to equity of $182.3 million. Cost of Equity Raise Costs incurred in raising equity, whether paid with cash or through the issuance of securities, are charged against the equity raised. These costs include underwriting discounts and commissions, legal fees, accounting services and amounts paid to consultants and amounted to $11.7 million, cumulatively, as of the IPO date. $1.8 million of these costs were deferred and included within other long-term assets on the consolidated balance sheet as of December 31, 2016. The total amount of $11.7 million was charged against the capital raised through the IPO. Common Stock Option Plans The Company has three common stock option plans adopted in 2013, 2007 and 2004 (the “Plans”) which authorize the grant of up to 11,800,000 common stock options to employees, directors, and consultants. Additionally, on June 14, 2017, the Company adopted its 2017 Omnibus Incentive Plan and 2017 Employee Stock Purchase Plan (the “2017 Plans”). Under the 2017 Plans, 5,200,000 shares of common stock are reserved for future issuance to employees, directors, and consultants, including 1,000,000 reserved for an Employee Stock Purchase Plan, which was established at IPO but no shares have as yet been issued. Management has valued the options at their grant date using the Black-Scholes option pricing model. See Note 11— Stock-Based Compensation for more information.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	11. Stock-Based Compensation Stock Options The total fair-value of stock options vested and recorded as compensation expense during the three months ended September 30, 2017 and 2016 and the nine months ended September 30, 2017 and 2016 was $2.3 million, $2.3 million, $5.7 million, and $6.2 million, respectively. As of September 30, 2017 and December 31, 2016, $15.8 million and $11.0 million of unrecognized cost related to non-vested stock options was expected to be recognized over a weighted-average period of approximately 1.9 years and 1.6 years, respectively. The total intrinsic value of options exercised was approximately $1.6 million and less than $0.1 million for the nine months ended September 30, 2017 and 2016, respectively. The following table summarizes the status of the Company’s stock option activity granted under the Plans to employees, directors, and consultants (in thousands, except stock option amounts): Stock Options Weighted- Average Exercise price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2016 9,280,689 $ 6.26 7.26 $ 43,994 Granted 1,691,232 11.28 - Exercised (178,520 ) 6.77 - Forfeited (86,677 ) 8.96 - Expired (9,323 ) 3.57 - Outstanding at September 30, 2017 10,697,401 $ 7.02 7.26 $ 112,169 Vested and exercisable at September 30, 2017 7,887,583 $ 5.99 6.56 $ 90,862 The Company determines the fair value of stock-based awards on the grant date using the Black-Scholes option pricing model, which is impacted by assumptions regarding a number of highly subjective variables. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model during the periods indicated: Nine months ended Nine months ended September 30, 2017 September 30, 2016 Weighted average grant date fair value $ 6.90 $ 5.29 Expected dividend yield - % - % Expected stock price volatility 66 % 65 % Risk-free interest rate 1.74 % 1.19 % Expected life of options (in years) 6.2 5.9 Stock Grants The Company grants common stock to key officers and directors as additional compensation in certain circumstances. The fair value of these grants is recorded as compensation expense throughout the requisite service period. Compensation cost recorded for the stock grants amounted to $0.5 million and $1.8 million for the three months ended September 30, 2017 and 2016, respectively, and $6.0 million and $4.0 million for the nine months ended September 30, 2017 and 2016, respectively. Awards granted to non-employees The Company has accounted for equity instruments issued to non-employees in accordance with the provisions of ASC 718, Compensation—Stock Compensation Equity Restricted Stock The following table summarizes restricted stock activity: Shares of Restricted Stock Weighted Average Fair Value Nonvested at December 31, 2016 661,982 $ 9.00 Granted - 9.00 Vested (421,982 ) 9.00 Nonvested at September 30, 2017 240,000 $ 9.00 Warrants The Company has granted warrants to purchase common stock. The Company determined the fair value of the warrants on the grant date using the Black-Scholes option pricing model, consistent with the valuations of stock options described above. All warrants were fully vested and 344,000 were outstanding as of December 31, 2016. During June 2017, the holder exercised their warrants and as of September 30, 2017, there were no outstanding warrants. Stock-Based Compensation Cost The components of stock-based compensation and the amounts recorded within research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the three and nine months ended September 30, 2017 and 2016 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Stock options $ 2,349 $ 2,319 $ 5,690 $ 6,196 Vesting of restricted stock grants 540 1,806 1,620 3,973 Stock awarded to directors and officers - - 4,400 - Total stock-based compensation expense $ 2,889 $ 4,125 $ 11,710 $ 10,169 Cost of product sales $ 48 $ - $ 96 $ - Research and development expenses 567 1,820 1,475 4,984 Selling, general, and administrative expenses 2,274 2,305 10,139 5,185 Total stock-based compensation expense $ 2,889 $ 4,125 $ 11,710 $ 10,169

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Athenex, Inc. Common Stockholders	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Athenex, Inc. Common Stockholders	12. Net Loss Per Share Attributable to Athenex, Inc. Common Stockholders Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares issued, outstanding, and vested during the period. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share and common shares equivalents for the period using the treasury-stock method. For the purposes of this calculation, warrants for common stock and stock options are considered common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Stock options and other common stock equivalents 10,736,494 11,340,938 9,989,045 11,250,456 Unvested restricted shares 265,000 1,434,548 444,544 1,427,370 Total potential dilutive shares 11,001,494 12,775,486 10,433,589 12,677,826

Business Segment, Geographic, a

Business Segment, Geographic, and Concentration Risk Information	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Business Segment, Geographic, and Concentration Risk Information	13. Business Segment, Geographic, and Concentration Risk Information The Company has three operating segments, which are organized based mainly on the nature of the business activities performed and regulatory environments in which they operate. The Company also considers the types of products from which the reportable segments derive their revenue (only applicable to two reportable segments). Each operating segment has a segment manager who is held accountable for operations and has discrete financial information that is regularly reviewed by the Company’s chief operating decision-maker. The Company’s operating segments are as follows: Oncology Innovation Platform —This operating segment performs research and development on certain of the Company’s proprietary drugs, from the preclinical development of its chemical compounds, to the execution and analysis of its several clinical trials. This segment focuses specifically on the oral absorption cancer drug platform, the Src Kinase inhibitors, and the transmucosal drug delivery system. This segment performs research in the United States, Taiwan, Hong Kong, and mainland China. Global Supply Chain Platform —This operating segment includes Athenex Pharma Solutions and Polymed. Athenex Pharma Solutions is a contract manufacturing company that provides small to mid-scale cGMP manufacturing of clinical and commercial products for pharmaceutical and biotech companies. Athenex Pharma Solutions also performs microbiological and analytical testing for raw material and formulated products and is expanding to manufacture and sell pharmaceutical products under 503B regulations set forth by the U.S. Food and Drug Administration (“FDA”). Polymed markets and sells API and medical devices in North America, Europe, and Asia from its locations in Texas and China. Polymed also develops new compounds, processing techniques, and manufactures API at Taihao, a cGMP facility in Chongqing, China. Currently, a majority of the Company’s revenue is generated by this segment. Commercial Platform —This operating segment includes Athenex Pharmaceutical Division, a newly-formed component that is focused on the manufacturing, distribution, and sales of generic pharmaceuticals. This segment provides services and products to external customers based mainly in the United States. The segments operate in North America and Asia. The Company’s Oncology Innovation Platform segment operates and holds long-lived assets located in the United States, Taiwan, Hong Kong, and mainland China. The Commercial Platform segment operates and holds long-lived assets located in the United States. The Global Supply Chain Platform segment operates and holds long-lived assets located in the United States and China. For geographic segment reporting, product sales have been attributed to countries based on the location of the customer. Segment information is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net (loss) income attributable to Athenex, Inc.: Oncology Innovation Platform $ (22,558 ) $ (17,989 ) $ (83,836 ) $ (40,441 ) Global Supply Chain Platform (1,564 ) (248 ) (4,693 ) (23 ) Commercial Platform 848 (6,385 ) (14,358 ) (7,197 ) Total consolidated net loss attributable to Athenex, Inc. $ (23,274 ) $ (24,622 ) $ (102,887 ) $ (47,661 ) Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Total revenue: Oncology Innovation Platform $ 205 $ 123 $ 1,208 $ 669 Global Supply Chain Platform 8,601 7,767 19,407 19,371 Commercial Platform 7,378 - 9,274 - Total revenue for reportable segments 16,184 7,890 29,889 20,040 Intersegment revenue (2,190 ) (2,274 ) (6,719 ) (4,602 ) Total consolidated revenue $ 13,994 $ 5,616 $ 23,170 $ 15,438 Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Total revenue by product group: API sales $ 5,345 $ 4,051 $ 10,369 $ 11,740 Medical device sales 562 649 1,128 1,525 Contract manufacturing revenue 250 517 934 1,229 Commercial product sales 7,505 18 9,547 50 License fees and consulting revenue 60 75 756 241 Grant revenue 272 306 436 653 Total consolidated revenue $ 13,994 $ 5,616 $ 23,170 $ 15,438 Intersegment revenue is recorded by the selling segment when it is realized or realizable and all revenue recognition criteria are met. Upon consolidation, all intersegment revenue and related cost of sales are eliminated from the selling segment’s ledger. Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Total depreciation and amortization: Oncology Innovation Platform $ 130 $ 49 $ 342 $ 146 Global Supply Chain Platform 548 484 1,569 1,139 Commercial Platform 243 45 674 45 Total consolidated depreciation and amortization $ 921 $ 578 $ 2,585 $ 1,330 September 30, December 31, 2017 2016 Total assets: Oncology Innovation Platform $ 85,450 $ 53,022 Global Supply Chain Platform 47,864 48,560 Commercial Platform 15,444 4,308 Total consolidated assets $ 148,758 $ 105,890 Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Total revenue: United States $ 8,114 $ 1,060 $ 11,056 $ 2,575 India 3,015 2,156 5,275 5,364 Austria 964 1,514 2,682 4,698 China 1,038 521 1,767 1,627 Taiwan - - 500 - Other foreign countries 863 365 1,890 1,174 Total consolidated revenue $ 13,994 $ 5,616 $ 23,170 $ 15,438 September 30, December 31, 2017 2016 Total property and equipment, net: United States $ 4,609 $ 2,177 China 4,215 3,633 Total consolidated property and equipment, net $ 8,824 $ 5,810 Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment. Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Percentage of total revenue by customer: Customer A 18 % 38 % 20 % 35 % Customer B 7 % 27 % 11 % 29 % Customer C 16 % - 11 % - Customer D 7 % - 7 % - September 30, December 31, 2017 2016 Percentage of total accounts receivable by customer: Customer A 25 % 50 % Customer B 8 % 9 % Customer C 11 % -

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Future minimum payments under the non-cancelable leases consisted of the following as of September 30, 2017 (in thousands): Year ending December 31: Minimum payments 2017 (remaining three months) $ 211 2018 1,263 2019 1,648 2020 1,657 2021 1,665 Thereafter 6,295 $ 12,739 Legal Proceedings The Company is not a party to any pending or known threatened legal proceedings that, in the opinion of the Company, would have a material impact on the Company’s condensed consolidated financial statements.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments ) considered necessary for a fair presentation of the results of the Company for the periods presented. These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. Intercompany transactions and balances have been fully eliminated in consolidation. Results of the operations for the three and nine months ended September 30, 2017 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes for the years ended December 31, 2015 and 2016 included in the prospectus dated June 15, 2017, filed with the SEC pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended.
Use of Estimates	Use of Estimates These condensed consolidated financial statements have been prepared in conformity with GAAP. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in contract research accruals, allowance for doubtful accounts, chargebacks, inventory reserves, income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition Product Sales, Chargebacks, Returns, and Discounts The Company recognizes product revenue when there is persuasive evidence of an arrangement, the price is fixed or determinable, collectability is reasonably assured, and upon shipment to or delivery and acceptance by customers. Service revenue is recognized in the period such services have been rendered. The Company’s specialty products sold through its Commercial Platform are distributed through independent pharmaceutical wholesalers. The wholesalers then generally sell to an end-user, normally a hospital, alternative healthcare facility, or an independent pharmacy, at a lower price previously established by the end-user and the Company. Sales are initially recorded at the list price sold to the wholesaler. Because these prices will be reduced for the end-user, the Company records a contra asset in accounts receivable and a reduction to revenue at the time of the sale, using the difference between the list price and the estimated end-user contract price. Upon the sale by the wholesaler to the end-user, the wholesaler will chargeback the difference between the original list price and price at which the product was sold to the end-user and such chargeback is offset against the initial estimated contra asset. As of September 30, 2017, the Company’s chargeback provision totaled $2.6 million. The Company offers cash discounts, which approximate 2% of the gross sales price as an incentive for prompt customer payment, and, consistent with industry practice, the Company’s return policy permits customers to return products within a window of time before and after the expiration of product dating, most often 2% of gross purchases. The Company expects that its wholesale customers will make timely payments and take advantage of the cash discounts, and expects customers to use their right of return. Therefore, at the time of sale, product revenue and accounts receivable are reduced by the full amount of the discount offered and the return expected. The Company considers payment performance and historical return rates and adjusts the accrual to reflect actual experience. As of September 30, 2017, the Company’s accrual for cash discounts and return accrual were not material to the financial statements.
Concentration of Credit Risk, Other Risks and Uncertainties	Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and investments. The Company deposits its cash equivalents in interest-bearing money market accounts and certificates of deposit. Although the Company deposits the cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility in China, Taihao, and therefore is subject to foreign currency fluctuation. Also, due to government restrictions on transferring funds out of China, the total restricted net assets of the Company’s consolidated subsidiaries was $12.7 million and $15.7 million as of September 30, 2017 and December 31, 2016, respectively.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) No. 2014-09, “ Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued ASU No. 2016-02, “ Leases (Topic 842) In June 2016, the FASB issued ASU No. 2016-13, “ Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In October 2016, the FASB issued ASU 2016-16, “ Income Taxes (Topic 740): Intra-entity Transfers of Assets Other Than Inventory In November 2016, the FASB issued ASU 2016-18, “ Statement of Cash Flows (Topic 230): Restricted Cash
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In July 2015, the FASB issued ASU No. 2015-11, “ Inventory (Topic 330): Simplifying the Measurement of Inventory. In March 2016, the FASB issued ASU No. 2016-09, “ Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In January 2017, the FASB issued ASU 2017-04, “ Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands): September 30, 2017 December 31, 2016 Raw materials and purchased parts $ 934 $ 977 Work in progress 2,298 2,727 Finished goods 8,403 536 Total inventories $ 11,635 $ 4,240

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Identifiable Intangible Asset, Net	The Company’s identifiable intangible assets, net, consist of the following (in thousands): December 31, 2016 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 3,100 $ 315 $ - $ 2,785 QuaDPharma customer list 204 58 146 - Polymed customer list 1,593 414 - 1,179 Polymed technology 3,712 437 - 3,275 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,884 - 248 1,636 Effect of currency translation adjustment (411 ) - - (411 ) Total intangible assets, net $ 10,082 $ 1,224 $ 394 $ 8,464 September 30, 2017 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 4,650 $ 952 $ - $ 3,698 Polymed customer list 1,593 611 - 982 Polymed technology 3,712 672 - 3,040 Product rights 530 100 - 430 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,106 - 80 1,026 Effect of currency translation adjustment (271 ) - - (271 ) Total intangible assets, net $ 11,320 $ 2,335 $ 80 $ 8,905

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at December 31, 2016 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 6,522 $ 6,522 $ - $ - Short-term investments - certificates of deposit 8,628 8,628 - - Investment 340 340 - - Total assets $ 15,490 $ 15,490 $ - $ - Liabilities: Derivative liability $ 8,795 $ - $ - $ 8,795 Total liabilities $ 8,795 $ - $ - $ 8,795 Fair Value Measurements at September 30, 2017 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 7,706 $ 7,706 $ - $ - Short-term investments - commercial paper 22,198 - 22,198 - Short-term investments - corporate notes 10,084 - 10,084 - Short-term investments - U.S. government bonds 19,498 - 19,498 - Investment 325 325 - - Total assets $ 59,811 $ 8,031 $ 51,780 $ -
Summary of Changes in Fair Value of Company's Level 3 Financial Instruments	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments (in thousands): Derivative Liability Balance as of December 31, 2016 $ 8,795 Issuance of convertible bonds with embedded derivative 13,172 Change in fair value 15,411 Conversion of derivative liability to common stock (37,378 ) Balance as of September 30, 2017 $ -

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Components of Debt	As of September 30, 2017 and December 31, 2016, the balances of this debt are as follows (in thousands): September 30, 2017 December 31, 2016 Current portion of promissory notes to related parties $ 779 $ 1,123 Current portion of mortgage 798 766 Current portion of capital lease obligation 44 - Long-term portion of promissory notes to related parties - 496 Long-term portion of capital lease obligation 179 - Convertible bonds - 14,498 Convertible bonds - related parties - 16,129 Derivative liability - 8,795 Total $ 1,800 $ 41,807

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Option Activity	The following table summarizes the status of the Company’s stock option activity granted under the Plans to employees, directors, and consultants (in thousands, except stock option amounts): Stock Options Weighted- Average Exercise price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2016 9,280,689 $ 6.26 7.26 $ 43,994 Granted 1,691,232 11.28 - Exercised (178,520 ) 6.77 - Forfeited (86,677 ) 8.96 - Expired (9,323 ) 3.57 - Outstanding at September 30, 2017 10,697,401 $ 7.02 7.26 $ 112,169 Vested and exercisable at September 30, 2017 7,887,583 $ 5.99 6.56 $ 90,862
Schedule of Weighted Average Assumptions Used as Inputs to Black-Scholes Model	The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model during the periods indicated: Nine months ended Nine months ended September 30, 2017 September 30, 2016 Weighted average grant date fair value $ 6.90 $ 5.29 Expected dividend yield - % - % Expected stock price volatility 66 % 65 % Risk-free interest rate 1.74 % 1.19 % Expected life of options (in years) 6.2 5.9
Schedule of Restricted Stock Activity	The following table summarizes restricted stock activity: Shares of Restricted Stock Weighted Average Fair Value Nonvested at December 31, 2016 661,982 $ 9.00 Granted - 9.00 Vested (421,982 ) 9.00 Nonvested at September 30, 2017 240,000 $ 9.00
Schedule of Stock-Based Compensation Cost	The components of stock-based compensation and the amounts recorded within research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the three and nine months ended September 30, 2017 and 2016 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Stock options $ 2,349 $ 2,319 $ 5,690 $ 6,196 Vesting of restricted stock grants 540 1,806 1,620 3,973 Stock awarded to directors and officers - - 4,400 - Total stock-based compensation expense $ 2,889 $ 4,125 $ 11,710 $ 10,169 Cost of product sales $ 48 $ - $ 96 $ - Research and development expenses 567 1,820 1,475 4,984 Selling, general, and administrative expenses 2,274 2,305 10,139 5,185 Total stock-based compensation expense $ 2,889 $ 4,125 $ 11,710 $ 10,169

Net Loss Per Share Attributab28

Net Loss Per Share Attributable to Athenex, Inc. Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Schedule Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Stock options and other common stock equivalents 10,736,494 11,340,938 9,989,045 11,250,456 Unvested restricted shares 265,000 1,434,548 444,544 1,427,370 Total potential dilutive shares 11,001,494 12,775,486 10,433,589 12,677,826

Business Segment, Geographic,29

Business Segment, Geographic, and Concentration Risk Information (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Summary of Segment Information	Segment information is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Net (loss) income attributable to Athenex, Inc.: Oncology Innovation Platform $ (22,558 ) $ (17,989 ) $ (83,836 ) $ (40,441 ) Global Supply Chain Platform (1,564 ) (248 ) (4,693 ) (23 ) Commercial Platform 848 (6,385 ) (14,358 ) (7,197 ) Total consolidated net loss attributable to Athenex, Inc. $ (23,274 ) $ (24,622 ) $ (102,887 ) $ (47,661 )
Summary of Revenue by Segments	Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Total revenue: Oncology Innovation Platform $ 205 $ 123 $ 1,208 $ 669 Global Supply Chain Platform 8,601 7,767 19,407 19,371 Commercial Platform 7,378 - 9,274 - Total revenue for reportable segments 16,184 7,890 29,889 20,040 Intersegment revenue (2,190 ) (2,274 ) (6,719 ) (4,602 ) Total consolidated revenue $ 13,994 $ 5,616 $ 23,170 $ 15,438
Summary of Revenue by Product Group	Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Total revenue by product group: API sales $ 5,345 $ 4,051 $ 10,369 $ 11,740 Medical device sales 562 649 1,128 1,525 Contract manufacturing revenue 250 517 934 1,229 Commercial product sales 7,505 18 9,547 50 License fees and consulting revenue 60 75 756 241 Grant revenue 272 306 436 653 Total consolidated revenue $ 13,994 $ 5,616 $ 23,170 $ 15,438
Summary of Depreciation, Amortization and Assets by Segment	Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Total depreciation and amortization: Oncology Innovation Platform $ 130 $ 49 $ 342 $ 146 Global Supply Chain Platform 548 484 1,569 1,139 Commercial Platform 243 45 674 45 Total consolidated depreciation and amortization $ 921 $ 578 $ 2,585 $ 1,330 September 30, December 31, 2017 2016 Total assets: Oncology Innovation Platform $ 85,450 $ 53,022 Global Supply Chain Platform 47,864 48,560 Commercial Platform 15,444 4,308 Total consolidated assets $ 148,758 $ 105,890
Summary of Revenue by Geographical Segment	Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Total revenue: United States $ 8,114 $ 1,060 $ 11,056 $ 2,575 India 3,015 2,156 5,275 5,364 Austria 964 1,514 2,682 4,698 China 1,038 521 1,767 1,627 Taiwan - - 500 - Other foreign countries 863 365 1,890 1,174 Total consolidated revenue $ 13,994 $ 5,616 $ 23,170 $ 15,438
Summary of Property and Equipment by Geographical Segment	September 30, December 31, 2017 2016 Total property and equipment, net: United States $ 4,609 $ 2,177 China 4,215 3,633 Total consolidated property and equipment, net $ 8,824 $ 5,810
Summary of Customer Revenue and Accounts Receivable Concentration	Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment. Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Percentage of total revenue by customer: Customer A 18 % 38 % 20 % 35 % Customer B 7 % 27 % 11 % 29 % Customer C 16 % - 11 % - Customer D 7 % - 7 % - September 30, December 31, 2017 2016 Percentage of total accounts receivable by customer: Customer A 25 % 50 % Customer B 8 % 9 % Customer C 11 % -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Payments Under Non-Cancelable Leases	Future minimum payments under the non-cancelable leases consisted of the following as of September 30, 2017 (in thousands): Year ending December 31: Minimum payments 2017 (remaining three months) $ 211 2018 1,263 2019 1,648 2020 1,657 2021 1,665 Thereafter 6,295 $ 12,739

Company and Nature of Business

Company and Nature of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Sep. 29, 2017	Jun. 14, 2017	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016
Subsidiary Or Equity Method Investee [Line Items]
Accumulated deficit			$ 297,993	$ 297,993	$ 195,106
Common stock, shares issued			59,668,184	59,668,184	42,342,706
Convertible bonds, carrying value		$ 55,800
Convertible Bonds
Subsidiary Or Equity Method Investee [Line Items]
Convertible bonds, aggregate principal value	$ 7,000	68,000
Convertible bonds, carrying value		$ 55,800
Common stock discount rate	20.00%
Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Aggregate cash proceeds net of underwriting discounts and commissions and offering costs			$ 64,200
Underwriting discounts and commissions			6,100	$ 6,100
Offering costs			$ 5,600	$ 5,600
Common Stock | Convertible Bonds
Subsidiary Or Equity Method Investee [Line Items]
Shares issued upon conversion	795,455	7,727,273
IPO
Subsidiary Or Equity Method Investee [Line Items]
Common stock, shares issued			6,900,000	6,900,000
Common stock share price			$ 11	$ 11
IPO | Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Common stock share price			$ 11	$ 11
IPO | Common Stock | Convertible Bonds
Subsidiary Or Equity Method Investee [Line Items]
Common stock share price	$ 11
Shares issued upon conversion				8,522,728

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Chargeback provision	$ 2.6
Revenue recognition cash discount percentage	2.00%
Restricted net assets of the company's consolidated subsidiaries	$ 12.7	$ 15.7

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials and purchased parts	$ 934	$ 977
Work in progress	2,298	2,727
Finished goods	8,403	536
Total inventories	$ 11,635	$ 4,240

Intangible Assets, Net - Summar

Intangible Assets, Net - Summary of Identifiable Intangible Asset, Net (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Accumulated Amortization	$ 2,335	$ 1,224
Intangible asset, Effect of currency translation adjustment	(271)	(411)
Intangible assets Cost/Fair Value	11,320	10,082
Intangible assets Impairments	80	394
Intangible assets, net	8,905	8,464
CDE In- Process Research and Development
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost/Fair Value	1,106	1,884
Indefinite-lived intangible asset, Impairments	80	248
Indefinite-lived intangible asset, Net	1,026	1,636
Licensing Agreements
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	4,650	3,100
Finite-lived intangible asset, Accumulated Amortization	952	315
Finite-lived intangible asset, Net	3,698	2,785
Quad Pharma Customer List
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value		204
Finite-lived intangible asset, Accumulated Amortization		58
Finite-lived intangible asset, Impairments		146
Polymed Customer List
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	1,593	1,593
Finite-lived intangible asset, Accumulated Amortization	611	414
Finite-lived intangible asset, Net	982	1,179
Polymed Technology
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	3,712	3,712
Finite-lived intangible asset, Accumulated Amortization	672	437
Finite-lived intangible asset, Net	3,040	$ 3,275
Product Rights
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	530
Finite-lived intangible asset, Accumulated Amortization	100
Finite-lived intangible asset, Net	$ 430

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments			$ 80		$ 394
Weighted-average useful life of intangible assets			7 years 10 months 28 days
Amortization expense of intangible assets	$ 400	$ 200	$ 1,200	$ 500
Research and Development Expenses
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments			100
Licensing Agreements | Hanmi Pharmaceuticals Co. Ltd.
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired					$ 400
Acquired finite-lived intangible assets, amortization period					12 years 9 months
Licensing Agreements | Gland Pharma Ltd
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 1,600		$ 2,700
Acquired finite-lived intangible assets, amortization period			5 years		5 years
Customer List | Athenex Pharma Solutions
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period					7 years
Customer List | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period					6 years
Polymed Technology | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period					12 years

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assets, Level 1 to Level 2 transfers	$ 0	$ 0
Fair value assets, Level 2 to Level 1 transfers	0	0
Fair value liabilities, Level 1 to Level 2 transfers	0	0
Fair value liabilities, Level 2 to Level 1 transfers	0	0
Fair value assets, transfers into Level 3	0	0
Fair value assets, transfers out of Level 3	0	0
Fair value liabilities, transfers into Level 3	0	0
Fair value liabilities, transfers out of Level 3	$ 0	$ 0
Pharma Essentia | Taiwan OTC Exchange (TWO) | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of shares owned by company	68,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Assets:
Total assets	$ 59,811	$ 15,490
Liabilities:
Total liabilities		8,795
Derivative Liability
Liabilities:
Total liabilities		8,795
Money Market Funds
Assets:
Total assets	7,706	6,522
Short-term Investments - Certificates of Deposit
Assets:
Total assets		8,628
Investment
Assets:
Total assets	325	340
Short-term Investments - Commercial Paper
Assets:
Total assets	22,198
Short-term Investments - Corporate Notes
Assets:
Total assets	10,084
Short-term investments - U.S. Government Bonds
Assets:
Total assets	19,498
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total assets	8,031	15,490
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds
Assets:
Total assets	7,706	6,522
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term Investments - Certificates of Deposit
Assets:
Total assets		8,628
Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment
Assets:
Total assets	325	340
Significant Other Observable Inputs (Level 2)
Assets:
Total assets	51,780
Significant Other Observable Inputs (Level 2) | Short-term Investments - Commercial Paper
Assets:
Total assets	22,198
Significant Other Observable Inputs (Level 2) | Short-term Investments - Corporate Notes
Assets:
Total assets	10,084
Significant Other Observable Inputs (Level 2) | Short-term investments - U.S. Government Bonds
Assets:
Total assets	$ 19,498
Significant Unobservable Inputs (Level 3)
Liabilities:
Total liabilities		8,795
Significant Unobservable Inputs (Level 3) | Derivative Liability
Liabilities:
Total liabilities		$ 8,795

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Financial Instruments (Details) - Derivative Liability $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2016	$ 8,795
Issuance of convertible bonds with embedded derivative	13,172
Change in fair value	15,411
Conversion of derivative liability to common stock	$ (37,378)

Debt - Summary of Balances of D

Debt - Summary of Balances of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 14, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Current portion of promissory notes to related parties	$ 779		$ 1,123
Current portion of mortgage	798		766
Current portion of capital lease obligation	44
Long-term portion of promissory notes to related parties			496
Long-term portion of capital lease obligation	179
Convertible bonds			14,498
Convertible bonds - related parties		$ 24,000	16,129
Derivative liability			8,795
Total	$ 1,800		$ 41,807

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 29, 2017	Jun. 14, 2017	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Mortgage payment extended date					Jul. 30, 2018
Future minimum principal payment			$ 1,100		$ 1,100
Future minimum principal payment			500		500
Convertible bonds		$ 24,000				$ 16,129
Amount converted to common stock		68,000			98,929
Convertible debt carrying value		$ 55,800
Shares issued in conversion		7,727,273
Loss on embedded derivative feature from convertible bond			$ 6,548		$ 15,411
IPO
Debt Instrument [Line Items]
Common stock share price			$ 11		$ 11
Common Stock | IPO
Debt Instrument [Line Items]
Common stock share price			$ 11		$ 11
Convertible Bonds
Debt Instrument [Line Items]
Convertible debt carrying value		$ 55,800
Convertible bonds, aggregate principal value	$ 7,000	$ 68,000
Common stock discount rate	20.00%
Convertible Bonds | Common Stock
Debt Instrument [Line Items]
Shares issued upon conversion	795,455	7,727,273
Convertible Bonds | Common Stock | IPO
Debt Instrument [Line Items]
Shares issued upon conversion					8,522,728
Common stock share price	$ 11
License Agreement | Hanmi
Debt Instrument [Line Items]
Convertible bonds				$ 7,000
License upfront fees payable				$ 7,000
License Agreement | Hanmi | Bond
Debt Instrument [Line Items]
Promissory note maturity, ending date				Oct. 1, 2018
Interest rate				10.00%
Loss on embedded derivative feature from convertible bond			$ 6,500
License Agreement | Hanmi | Convertible Bonds
Debt Instrument [Line Items]
Convertible bonds, aggregate principal value	$ 7,000
Common stock discount rate	20.00%
License Agreement | Hanmi | Convertible Bonds | Common Stock
Debt Instrument [Line Items]
Shares issued upon conversion	795,455
License Agreement | Hanmi | Convertible Bonds | Common Stock | IPO
Debt Instrument [Line Items]
Common stock share price	$ 11
Convertible Bonds
Debt Instrument [Line Items]
Promissory note maturity, ending date					Oct. 1, 2018
Convertible bonds issued by company			$ 75,000		$ 75,000	$ 75,000
Promissory Note
Debt Instrument [Line Items]
Promissory note maturity term					36 months
Promissory note maturity, ending date					Jun. 1, 2018
Interest rate			6.00%		6.00%

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2017USD ($)shares	Mar. 31, 2017USD ($)RelatedParty	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)shares	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)Executive	Dec. 31, 2014USD ($)Executive	Jun. 14, 2017shares
Related Party Transaction [Line Items]
Stock-based compensation expense recognized	$ 2,889,000		$ 4,125,000	$ 11,710,000	$ 10,169,000
Percentage of outstanding common stock holding		5.00%				5.00%
Convertible Bonds
Related Party Transaction [Line Items]
Amounts owed to related party	24,000,000	$ 4,000,000		$ 24,000,000		$ 24,000,000
Amount purchased in convertible bonds by holders of outstanding common stock and entity affiliate		$ 2,000,000				$ 10,000,000
Number of related parties received convertible bonds | RelatedParty		2
Bonds converted into shares of common stock | shares									2,727,273
Executive Officer
Related Party Transaction [Line Items]
Promissory notes issued							$ 12,600,000	$ 12,600,000
Number of executives | Executive							2	2
Promissory note maturity term				3 years
Stock-based compensation expense recognized	$ 0		1,000,000	$ 0	3,100,000
Avalon BioMedical
Related Party Transaction [Line Items]
Common stock shares held by related parties | shares	678,880			678,880		678,880
Percentage of common stock issued shares				1.10%		1.70%
Pharma Essentia
Related Party Transaction [Line Items]
Licenses revenue	$ 0		0	$ 500,000	0
Taisheng
Related Party Transaction [Line Items]
Purchases of pharmaceutical ingredients from related party	0		0	0	200,000
ZenRx
Related Party Transaction [Line Items]
Amounts owed to related party	100,000			100,000		$ 100,000
ZenRx | Clinical Development Services
Related Party Transaction [Line Items]
Payments to related party for services received	200,000			500,000
ZenRx | Clinical Development Services | Maximum
Related Party Transaction [Line Items]
Payments to related party for services received			100,000		100,000
RSJ Consulting LLC
Related Party Transaction [Line Items]
Consulting services incurred				$ 100,000	$ 200,000
RSJ Consulting LLC | Maximum
Related Party Transaction [Line Items]
Consulting services incurred	$ 100,000		$ 100,000

Business and Economic Collabo42

Business and Economic Collaborative Agreements - Additional Information (Details)	Sep. 04, 2017USD ($)ft²	May 01, 2015USD ($)
Grant Disbursement Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Area of building to be establish under agreement | ft²	315,000
Purchase rate of equipment per year in first 10 year term	$ 1
Purchase rate of equipment per year in second 10 year term	1
Operating expenses committed to spent in first 10 year term	1,520,000,000
Operating expenses committed to spent in second 10 year term	$ 1,500,000,000
Lease term	10 years
Renewal lease term	10 years
New York State
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from state		$ 25,000,000
New York State | Grant Disbursement Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from state	$ 200,000,000

Stockholders Equity - Additiona

Stockholders Equity - Additional Information (Details) $ / shares in Units, $ in Thousands	Sep. 29, 2017$ / sharesshares	Jun. 14, 2017USD ($)shares	Sep. 30, 2017USD ($)Plan$ / sharesshares	Sep. 30, 2016$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Class Of Stock [Line Items]
Common stock, shares authorized			250,000,000	250,000,000	250,000,000
Common stock, par value | $ / shares			$ 0.001	$ 0.001	$ 0.001
Common stock, voting rights			one vote per share
Costs incurred in raising equity | $		$ 11,700	$ 10,168
Number of stock option plans | Plan			3
2013, 2007 and 2004 Plans | Maximum
Class Of Stock [Line Items]
Common stock options authorized grant			11,800,000
2017 Plans
Class Of Stock [Line Items]
Common stock reserved for future issuance			5,200,000
Shares issued			0
Common Stock
Class Of Stock [Line Items]
Sale of common stock, shares			6,900,000	1,133,332
Convertible Bonds | Common Stock
Class Of Stock [Line Items]
Shares issued upon conversion	795,455	7,727,273
IPO
Class Of Stock [Line Items]
Sale of common stock, shares			6,900,000
Common stock share price | $ / shares			$ 11
Shares from the exercise of warrants and options			512,586
Vesting of restricted stock units and grant of shares			821,982
Cumulative increase to equity shares value | $			$ 182,300
Costs incurred in raising equity | $			$ 11,700
IPO | 2017 Plans
Class Of Stock [Line Items]
Common stock reserved for future issuance			1,000,000
IPO | Other Long-term Assets [Member]
Class Of Stock [Line Items]
Deferred costs | $					$ 1,800
IPO | Licensing Agreements
Class Of Stock [Line Items]
Sale of common stock, shares			568,182
IPO | Common Stock
Class Of Stock [Line Items]
Common stock share price | $ / shares			$ 11
IPO | Convertible Bonds | Common Stock
Class Of Stock [Line Items]
Common stock share price | $ / shares	$ 11
Shares issued upon conversion			8,522,728

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 2,889,000	$ 4,125,000	$ 11,710,000	$ 10,169,000
Warrants outstanding	0		0		344,000
Stock Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 500,000	1,800,000	$ 6,000,000	4,000,000
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	2,349,000	$ 2,319,000	5,690,000	6,196,000
Unrecognized cost related to non-vested stock options expected to be recognized	$ 15,800,000		$ 15,800,000		$ 11,000,000
Unrecognized cost related to non-vested stock options, weighted-average period of recognition			1 year 10 months 25 days		1 year 7 months 7 days
Intrinsic value of options exercised			$ 1,600,000
Stock Options | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options exercised				$ 100,000

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Stock Options
Stock Options, Outstanding Beginning Balance	9,280,689
Stock Options, Granted	1,691,232
Stock Options, Exercised	(178,520)
Stock Options, Forfeited	(86,677)
Stock Options, Expired	(9,323)
Stock Options, Outstanding Ending Balance	10,697,401	9,280,689
Stock Options, Vested and exercisable at September 30, 2017	7,887,583
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 6.26
Weighted Average Exercise Price, Granted	11.28
Weighted Average Exercise Price, Exercised	6.77
Weighted Average Exercise Price, Forfeited	8.96
Weighted Average Exercise Price, Expired	3.57
Weighted Average Exercise Price, Outstanding Ending Balance	7.02	$ 6.26
Weighted Average Exercise Price, Vested and exercisable at September 30, 2017	$ 5.99
Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term, Outstanding	7 years 3 months 4 days	7 years 3 months 4 days
Weighted Average Remaining Contractual Term, Vested and exercisable at September 30, 2017	6 years 6 months 21 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding	$ 112,169	$ 43,994
Aggregate Intrinsic Value, Vested and exercisable at September 30, 2017	$ 90,862

Stock Based Compensation - Sc46

Stock Based Compensation - Schedule of Weighted Average Assumptions Used as Inputs to Black-Scholes Model (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant date fair value	$ 6.90	$ 5.29
Expected stock price volatility	66.00%	65.00%
Risk-free interest rate	1.74%	1.19%
Expected life of options (in years)	6 years 2 months 12 days	5 years 10 months 25 days

Stock Based Compensation - Sc47

Stock Based Compensation - Schedule of Restricted Stock Activity (Details)	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Shares of Restricted Stock
Shares of Restricted Stock, Nonvested Beginning Balance | shares	661,982
Shares of Restricted Stock, Vested | shares	(421,982)
Shares of Restricted Stock, Nonvested Ending Balance | shares	240,000
Weighted Average Fair Value
Weighted Average Fair Value, Nonvested Beginning Balance	$ 9
Weighted Average Fair Value, Nonvested Granted	9
Weighted Average Fair Value, Nonvested Vested	9
Weighted Average Fair Value, Nonvested Ending Balance	$ 9

Stock Based Compensation - Sc48

Stock Based Compensation - Schedule of Stock-Based Compensation Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 2,889	$ 4,125	$ 11,710	$ 10,169
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	2,349	2,319	5,690	6,196
Vesting of Restricted Stock Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	540	1,806	1,620	3,973
Stock Awarded to Directors and Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized			4,400
Cost of Product Sales
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	48		96
Research and Development Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	567	1,820	1,475	4,984
Selling, General, and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 2,274	$ 2,305	$ 10,139	$ 5,185

Net Loss per Share Attributab49

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders - Schedule Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	11,001,494	12,775,486	10,433,589	12,677,826
Stock Options and Other Common Stock Equivalents [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	10,736,494	11,340,938	9,989,045	11,250,456
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	265,000	1,434,548	444,544	1,427,370

Business Segment, Geographic,50

Business Segment, Geographic, and Concentration Risk Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2017segment
Segment Reporting [Abstract]
Number of operating segments	3
Number of reportable segments	2

Business Segment, Geographic,51

Business Segment, Geographic, and Concentration Risk Information - Summary of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ (23,274)	$ (24,622)	$ (102,887)	$ (47,661)
Oncology Innovation Platform
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(22,558)	(17,989)	(83,836)	(40,441)
Global Supply Chain Platform
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(1,564)	(248)	(4,693)	(23)
Commercial Platform
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ 848	$ (6,385)	$ (14,358)	$ (7,197)

Business Segment, Geographic,52

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Segments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Total revenue:
Total consolidated revenue	$ 13,994	$ 5,616	$ 23,170	$ 15,438
Operating Segments
Total revenue:
Total consolidated revenue	16,184	7,890	29,889	20,040
Operating Segments | Oncology Innovation Platform
Total revenue:
Total consolidated revenue	205	123	1,208	669
Operating Segments | Global Supply Chain Platform
Total revenue:
Total consolidated revenue	8,601	7,767	19,407	19,371
Operating Segments | Commercial Platform
Total revenue:
Total consolidated revenue	7,378	0	9,274	0
Intersegment Eliminations
Total revenue:
Total consolidated revenue	$ (2,190)	$ (2,274)	$ (6,719)	$ (4,602)

Business Segment, Geographic,53

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Product Group (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Total revenue by product group:
Total consolidated revenue	$ 13,994	$ 5,616	$ 23,170	$ 15,438
API Sales
Total revenue by product group:
Total consolidated revenue	5,345	4,051	10,369	11,740
Medical Device Sales
Total revenue by product group:
Total consolidated revenue	562	649	1,128	1,525
Contract Manufacturing Revenue
Total revenue by product group:
Total consolidated revenue	250	517	934	1,229
Commercial Product Sales
Total revenue by product group:
Total consolidated revenue	7,505	18	9,547	50
License Fees and Consulting Revenue
Total revenue by product group:
Total consolidated revenue	60	75	756	241
Grant Revenue
Total revenue by product group:
Total consolidated revenue	$ 272	$ 306	$ 436	$ 653

Business Segment, Geographic,54

Business Segment, Geographic, and Concentration Risk Information - Summary of Depreciation, Amortization and Assets by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Total depreciation and amortization:
Total consolidated depreciation and amortization	$ 921	$ 578	$ 2,585	$ 1,330
Total assets:
Total consolidated assets	148,758		148,758		$ 105,890
Oncology Innovation Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	130	49	342	146
Total assets:
Total consolidated assets	85,450		85,450		53,022
Global Supply Chain Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	548	484	1,569	1,139
Total assets:
Total consolidated assets	47,864		47,864		48,560
Commercial Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	243	$ 45	674	$ 45
Total assets:
Total consolidated assets	$ 15,444		$ 15,444		$ 4,308

Business Segment, Geographic,55

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Geographical Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Total revenue:
Total consolidated revenue	$ 13,994	$ 5,616	$ 23,170	$ 15,438
United States
Total revenue:
Total consolidated revenue	8,114	1,060	11,056	2,575
India
Total revenue:
Total consolidated revenue	3,015	2,156	5,275	5,364
Austria
Total revenue:
Total consolidated revenue	964	1,514	2,682	4,698
China
Total revenue:
Total consolidated revenue	1,038	521	1,767	1,627
Taiwan
Total revenue:
Total consolidated revenue	0	0	500	0
Other Foreign Countries
Total revenue:
Total consolidated revenue	$ 863	$ 365	$ 1,890	$ 1,174

Business Segment, Geographic,56

Business Segment, Geographic, and Concentration Risk Information - Summary of Property and Equipment by Geographical Segment (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Total property and equipment, net:
Total consolidated property and equipment, net	$ 8,824	$ 5,810
United States
Total property and equipment, net:
Total consolidated property and equipment, net	4,609	2,177
China
Total property and equipment, net:
Total consolidated property and equipment, net	$ 4,215	$ 3,633

Business Segment, Geographic,57

Business Segment, Geographic, and Concentration Risk Information - Summary of Customer Revenue and Accounts Receivable Concentration (Details) - Commercial Platform and Global Supply Chain - Customer Concentration Risk	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Customer Revenue | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	18.00%	38.00%	20.00%	35.00%
Customer Revenue | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	7.00%	27.00%	11.00%	29.00%
Customer Revenue | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	16.00%		11.00%
Customer Revenue | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage	7.00%		7.00%
Accounts Receivable | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage			25.00%		50.00%
Accounts Receivable | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage			8.00%		9.00%
Accounts Receivable | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage			11.00%		0.00%

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Payments Under Non-Cancelable Leases (Details) $ in Thousands	Sep. 30, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
2017 (remaining three months)	$ 211
2,018	1,263
2,019	1,648
2,020	1,657
2,021	1,665
Thereafter	6,295
Future minimum payments under non-cancelable leases	$ 12,739